Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Neoplasms 10Glioblastoma 9Fallopian Tube Neoplasms 8Colorectal Neoplasms 8Breast Neoplasms 8Lung Neoplasms 7Rectal Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Brain Neoplasms 6Prostatic Neoplasms 4Melanoma 4Uterine Cervical Neoplasms 3Solitary Fibrous Tumor, Pleural 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Advanced Solid Tumor 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2

Interventions

carotuximab 2Methotrexate 2Leucovorin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dactinomycin 2Carboplatin 2Bevacizumab 2saracatinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1etoposide phosphate 1cediranib 1Thiotepa 1Specimen Handling 1Second-Look Surgery 1Reoperation 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1Mesna 1Magnetic Resonance Spectroscopy 1Filgrastim 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Choriocarcinoma × cediranib × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡